Brightline-1: A Phase II/III, randomized, open-label, multi-center study of BI 907828 compared to doxorubicin as first line treatment of patients with advanced dedifferentiated liposarcoma


NCT Number:



Study Status:






The purpose of this study is to test the study drug, BI 907828 for safety, effectiveness and side effects when compared to receiving the standard treatment, doxorubicin, in subjects with dedifferentiated liposarcoma (DDLPS). BI 907828 has proven to minimize a critical protein interaction between MDM2 and p53, two proteins in your body, which when their interaction is diminished, can stop the growth of your cancer. Patients with DDLPS are normally prescribed Doxorubicin as their standard treatment once they are diagnosed. The study also aims to find the recommended dose of the study drug, BI 907828 that can be used in the second part of this study (Part 2) and in future clinical research studies. We will ask you to take the study drug orally or take the FDA approved drug, doxorubicin, intravenously (in the vein). The time frame for the study depends on how long you decide to stay on BI 907828, the study drug.

Are you Eligible? (Inclusion Criteria)

  • You must be 18 years of age or older.
  • You must have been diagnosed with dedifferentiated liposarcoma.
  • You must be comfortable swallowing pills.

Specialty Area(s)

Sarcomas (Bone and Soft Tissue), Soft Tissue Sarcoma

Principal Investigator

Profile Headshot
  • Division Chief, Hematology/Oncology
  • Deputy Director, Herbert Irving Comprehensive Cancer Center

Trial Location(s)

CUIMC/Herbert Irving Pavilion
161 Fort Washington Avenue
New York, NY 10032